Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Leica Microsystems Signs Distribution Agreement with French Company

By Labmedica staff writers
Posted on 10 Apr 2007
Leica Microsystems (Wetzlar, Germany) and Mauna Kea Technologies (MKT; Paris, France) signed an exclusive distribution agreement for the German high-tech optics company to market the innovative system developed by Mauna Kea Technologies. More...
The two companies are collaborating to improve research and to discover therapies against serious diseases worldwide

Leica Microsystems thus enlarges its product portfolio to include an endoscopic confocal microscope for in-vivo research applications. The agreement covers Europe, North America, and Japan. Cellvizio, as the system is called, will be adopted marketed as Leica FCM1000 (fiber-confocal microscope).

Leica FCM1000 with Cellvizio technology is a fiberoptic confocal fluorescence microscope for dynamic in vivo imaging. Its movable, minimally invasive probe allows it to be introduced non-destructively into the insides of living animals, producing video image sequences at a rate of 12 frames per second. There is a strongly increasing demand for in vivo microscopy, to complement classical in-vitro studies, so this new product is the ideal addition to our portfolio of state of the art confocal microscopes, explained Leica's executive vice president of sales and marketing, David Martyr.

This small animal imaging system is used in pre-clinical research in academic research institutions and biotechnologic and pharmaceutic companies. Primarily conducted on rodents, these experiments play a key role in neurologic research in deep brain and peripheral nerves imaging, especially in the research of degenerative diseases such as Alzheimer's and Parkinson's, and in cancer, cardiovascular and stem cell research, gene delivery, and tissue engineering.

Sacha Loiseau, president of Mauna Kea Technologies, explained, We are extremely proud of this major agreement between Mauna Kea Technologies and the prestigious company Leica Microsystems. It tangibly recognizes MKT's innovative R&D and leadership in non-invasive cellular and molecular imaging solutions. This achievement is the result of MKT's effort to gather the best team of scientists and engineers to develop new imaging technologies that are perfectly adapted to customer needs. The commercial agreement with Leica Microsystems will make it possible for thousands of researchers worldwide to benefit from the breakthroughs offered by Leica FCM1000 with Cellvizio technology.


Related Links:
Leica Microsystems
Mauna Kea Technologies

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.